Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug combo for pancreatic cancer shows early promise, but trial halted

NCT ID NCT05325281

Terminated Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a drug called CPI-613 (devimistat) combined with chemotherapy and radiation for people with pancreatic cancer that cannot be surgically removed. The goal was to find the safest dose. Only 8 people took part before the study was stopped. While the approach aims to improve local tumor control, the trial was too small and too early to know if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CPI-613 (devimistat)
What this could lead to
If successful, this could point toward a new combination treatment for pancreatic cancer that is harder to treat.
What could go wrong
This was a very early, small phase 1 trial that was terminated early. It only tested safety and dosing, not whether the treatment actually works. Side effects from the drug and chemoradiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREAS ADENOCARCINOMA

Contacts and locations

Locations

  • Froedtert & the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.